NYSEAM:OGEN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$87.5m

Last Updated

2021/08/03 00:36 UTC

Data Sources

Company Financials +

Executive Summary

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. More Details


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Oragenics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OGEN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: OGEN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

21.1%

OGEN

0.9%

US Biotechs

-0.4%

US Market


1 Year Return

-35.8%

OGEN

21.4%

US Biotechs

34.4%

US Market

Return vs Industry: OGEN underperformed the US Biotechs industry which returned 24.5% over the past year.

Return vs Market: OGEN underperformed the US Market which returned 35.9% over the past year.


Shareholder returns

OGENIndustryMarket
7 Day21.1%0.9%-0.4%
30 Day12.2%-0.6%-0.4%
90 Day1.9%5.9%4.0%
1 Year-35.8%-35.8%23.1%21.4%36.5%34.4%
3 Year51.1%51.1%22.9%16.8%62.0%51.9%
5 Year-89.9%-89.9%43.7%32.4%121.8%97.2%

Long-Term Price Volatility Vs. Market

How volatile is Oragenics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Oragenics undervalued compared to its fair value and its price relative to the market?

2.62x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OGEN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OGEN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: OGEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OGEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OGEN is good value based on its PB Ratio (2.6x) compared to the US Biotechs industry average (2.8x).


Future Growth

How is Oragenics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-2.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if OGEN's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if OGEN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OGEN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Oragenics performed over the past 5 years?

-27.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OGEN is currently unprofitable.

Growing Profit Margin: OGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OGEN is unprofitable, and losses have increased over the past 5 years at a rate of 27.8% per year.

Accelerating Growth: Unable to compare OGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (32.6%).


Return on Equity

High ROE: OGEN has a negative Return on Equity (-73.41%), as it is currently unprofitable.


Financial Health

How is Oragenics's financial position?


Financial Position Analysis

Short Term Liabilities: OGEN's short term assets ($36.7M) exceed its short term liabilities ($868.9K).

Long Term Liabilities: OGEN's short term assets ($36.7M) exceed its long term liabilities ($446.5K).


Debt to Equity History and Analysis

Debt Level: OGEN's debt to equity ratio (0.3%) is considered satisfactory.

Reducing Debt: OGEN's debt to equity ratio has reduced from 2.7% to 0.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OGEN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OGEN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Oragenics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Mike Sullivan (65 yo)

0.25

Tenure

US$532,210

Compensation

Mr. Michael O. Sullivan, also known as Mike, CPA has been the Chief Financial Officer, Secretary and Treasurer of Oragenics, Inc. since February 06, 2012 and has been its Interim Principal Executive Office...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD532.21K) is about average for companies of similar size in the US market ($USD551.32K).

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: OGEN's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: OGEN's board of directors are seasoned and experienced ( 12.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 108.9%.


Top Shareholders

Company Information

Oragenics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oragenics, Inc.
  • Ticker: OGEN
  • Exchange: NYSEAM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$87.550m
  • Shares outstanding: 115.64m
  • Website: https://www.oragenics.com

Number of Employees


Location

  • Oragenics, Inc.
  • 4902 Eisenhower Boulevard
  • Suite 125
  • Tampa
  • Florida
  • 33634
  • United States

Listings


Biography

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The compa...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/03 00:36
End of Day Share Price2021/08/02 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.